- Home
- EFSC vs PTGX Comparison
EFSC vs PTGX Comparison
Compare EFSC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EFSC | PTGX |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 9.3B |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EFSC | PTGX |
|---|---|---|
| Price | $64.05 | $148.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $66.33 | ★ $108.23 |
| AVG Volume (30 Days) | 163.6K | ★ 443.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 9.94 | N/A |
| EPS | ★ 2.39 | 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $14.22 | $874.25 |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | ★ $26.55 | $61.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.18 | $57.90 |
| 52 Week High | $68.73 | $160.81 |
Technical Indicators
Market Signals| Indicator | EFSC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 46.83 |
| Support Level | $62.48 | $141.95 |
| Resistance Level | $67.75 | $160.81 |
| Average True Range (ATR) | 0.87 | 5.60 |
| MACD | 0.03 | -1.45 |
| Stochastic Oscillator | 43.67 | 13.03 |
Price Performance
Historical ComparisonAbout EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.